



2022 NTM Research Consortium Meeting

Thursday, October 27, 2022

Agenda

HOR D'OEUVRES

3:00pm-3:30pm

- | | |
|-----------------|---|
| 3:20pm – 3:30pm | Welcome, Introductions and Meetings Objectives
Kevin Winthrop , Oregon Health & Science University |
| 3:30pm – 6:45pm | NTM Consortium Site Updates |
| 3:30pm | University Health Network (Ted Marras) |
| 4:10pm | National Jewish Health (Charles Daley) |
| 4:50pm | Epidemiology and Population Studies Unit, Division of Intramural Research, NIAID
(D Rebecca Prevots) |
| 5:10pm | Pulmonary Branch, NHLBI (Kevin Fennelly) |
| 5:30pm | University of Texas Health Center at Tyler (Julie Philley and Richard Wallace) |
| 6:10pm | Oregon Health & Science University (Emily Henkle, Cara Varley, and Vince Groppi) |

DINNER

6:45pm

- | | |
|-----------------|--|
| 7:00pm – 8:00pm | Keynote Address |
| 7:00pm | Payam Nahid , University of California, San Francisco
<i>Tuberculosis drug development and therapeutic trials: what have we learned that could apply to NTM?</i> |

DESSERT & NETWORKING



2022 NTM Research Consortium Meeting

Friday, October 28, 2022

Agenda

CONTINENTAL BREAKFAST

8:00am-8:30am

- 8:30am – 8:40am **Welcome, Introductions, and Meeting Objectives**
Kevin Winthrop, Oregon Health & Science University
- 8:40am – 12:00pm **Biomarkers and Diagnostics**
- 8:40am **Jerry Nick**, National Jewish Health
NTM in Cystic Fibrosis and Biomarkers for Disease
- 9:15am **Tony Hu**, Tulane University
New diagnostic approaches to Mycobacterial---can we diagnose infection without sputum and monitor treatment success?
- 9:50am **Jakko van Ingen**, Radboud University Medical Center
Microbiologic endpoints and the best ways to measure them in clinical practice and in trials

BREAK

10:30am-10:45am

- 10:45am **David Lewinsohn**, Oregon Health & Science University
TB and NTM immunology: the potential for diagnosis and biomarkers of disease
- 11:25am **Ilhem Messaoudi**, Microbiology and Immunology, University of Kentucky College of Medicine
Longitudinal assessment of the immunological and microbial landscape of the lung during M. avium infection in rhesus macaques

LUNCH

12:00pm-12:45pm



2022 NTM Research Consortium Meeting

Friday, October 28, 2022

12:45pm-3:05pm

Non-Antimicrobial Approaches to NTM

12:45pm

Rachel Thomson, The University of Queensland
GM-CSF Therapy and NO therapy, proof of concept?

1:25pm

Graham Hatfull, University of Pittsburgh
Bacteriophage therapies for NTM and gram-negative chest infections

2:05pm

Jennifer Honda, National Jewish Health
Environmental approaches to NTM disease prevention

2:35pm

Karen Lacourciere & Barbara Laughon, National Institute of Allergy and Infectious Diseases
NIAID Non-Tuberculosis Mycobacterial Research Funding and Resources

BREAK

3:05pm-3:20pm

What's Cooking in Industry's Corner

3:20pm-5:05pm

What's Cooking in Industry's Corner

3:20pm

Hiwot Hiruy, Clinical Team Leader, Office of Infectious Diseases, U.S. F.D.A.
Development of Antibacterial Drugs for NTM: A Regulatory Perspective

3:35pm

Keira Cohen, Senior Medical Director, Early Clinical Development, Infectious Diseases, The Janssen Pharmaceutical Companies of Johnson & Johnson

3:50pm

Paul Eckburg, Chief Medical Officer, AN2 Therapeutics, Inc.

4:05pm

Dan Deck, Senior Director, Scientific Affairs, Paratek Pharmaceuticals

4:20pm

Kevin Mange, SVP, Head of Clinical Development, Insmed Incorporated

4:35pm

Enoch Bortey, SVP, Clinical Operations and Biometric, BeyondAir, Inc.

4:50pm

Kamal Hamed, Chief Medical Officer, Spero Therapeutics

DINNER & WINING

5:30pm-9:00pm